Candidate gene
Marker
Therapy target
| acting directly on the degree of its malonyl-CoA sensitivity may be a relevant strategy to prevent and/or correct hepatic steatosis |
|
System | Type | Disorder | Pubmed |
cardiovascular | atheroma | cardiac | |
potential targets for the treatment of metabolic disorders, including diabetes and coronary heart disease
| diabete | | | |
potential targets for the treatment of metabolic disorders, including diabetes and coronary heart disease | metabolism | lipid | | |
interventions that increase CPT1A activity could have potential benefits in the treatment of nonalcoholic fatty liver disease (NAFLD), hypertriglyceridemia |
| | |